Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000116.xml
Download PDF
Semin Vasc Med 2002; 2(2): 215-220
DOI: 10.1055/s-2002-32044
DOI: 10.1055/s-2002-32044
Hormone Replacement Therapy in Postmenopausal Women with Diabetes Mellitus
Further Information
Publication History
Publication Date:
06 June 2002 (online)
ABSTRACT
Postmenopausal women with type 2 diabetes mellitus have a high risk of cardiovascular disease. Hormone replacement therapy (HRT) with estrogens with or without progestagens relieves many climacteric symptoms. Although hormone replacement in theory could have beneficial effects on cardiovascular morbidity, to date no randomized controlled clinical trial has shown positive results in this regard. There are few data with respect to diabetic postmenopausal women.
There is no basis for prescription of HRT to diabetic women if the aim is to lower cardiovascular morbidity. On the other hand, there is also no reason not to prescribe HRT to diabetic women to treat climacteric symptoms.
KEYWORDS
Hormone replacement therapy - diabetes mellitus - cardiovascular risk profile - postmenopausal women
REFERENCES
- 1 Coope J, Thomson J M, Poller L. Effects of ``natural oestrogen'' replacement therapy on menopausal symptoms and blood clotting. BMJ . 1975; 4 139-143
- 2 Rosing J, Middeldorp S, Curvers J. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet . 1999; 354 2036-2040
- 3 Oleksik A M, Duong T, Pliester N, Asma G, Popp-Snijders C, Lips P. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab . 2001; 86 2763-2768
- 4 Nicodemus K K, Folsom A R. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care . 2001; 24 1192-1197
- 5 Barrett-Connor E, Bush T L. Estrogen and coronary heart disease in women. JAMA . 1991; 265 1861-1867
- 6 Grady D, Rubin S M, Petitti D B. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med . 1992; 117 1016-1037
- 7 Hulley S, Grady D, Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA . 1998; 280 605-613
- 8 Herrington D M, Reboussin D M, Brosnihan K B. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med . 2000; 343 522-529
- 9 Viscoli C M, Brass L M, Kernan W N, Sarrel P M, Suissa S, Horwitz R I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med . 2001; 345 1243-1249
- 10 Mosca L, Collins P, Herrington D M. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation . 2001; 104 499-503
- 11 Dunne F P. Should women with diabetes mellitus receive hormone replacement therapy?. Int J Clin Pract . 1997; 51 299-303
- 12 Knopp R H, Zhu X, Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis . 1994; 110(suppl) S83-S91
- 13 Palin S L, Kumar S, Sturdee D W, Barnett A H. Hormone replacement therapy for postmenopausal women with diabetes. Diabetes Obes Metab . 2001; 3 187-193
- 14 Feher M D, Isaacs A J. Is hormone replacement therapy prescribed for postmenopausal diabetic women?. Br J Clin Pract . 1996; 50 431-432
- 15 Moorhead T, Hannaford P, Warskyj M. Prevalence and characteristics associated with use of hormone replacement therapy in Britain. Br J Obstet Gynaecol . 1997; 104 290-297
- 16 Keating N L, Cleary P D, Rossi A S, Zaslavsky A M, Ayanian J Z. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med . 1999; 130 545-553
- 17 Kaplan R C, Heckbert S R, Weiss N S. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care . 1998; 21 1117-1121
- 18 Chmouliovsky L, Habicht F, James R W, Lehmann T, Campana A, Golay A. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. Maturitas . 1999; 32 147-153
- 19 van Baal M W, Kooistra T, Stehouwer C D. Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women. Curr Med Chem . 2000; 7 499-517
- 20 The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA . 1995; 273 199-208
- 21 Kornhauser C, Malacara J M, Garay M E, Perez-Luque E L. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. J Hum Hypertens . 1997; 11 405-411
- 22 van Ittersum J F, van Baal M W, Kenemans P. Ambulatory-not office-blood pressures decline during hormone replacement therapy in healthy postmenopausal women. Am J Hypertens . 1998; 11 1147-1152
- 23 van Baal M W, Emeis J J, van der Mooren J M, Kessel H, Kenemans P, Stehouwer C D. Impaired procoagulant-anticoagulant balance during hormone replacement therapy?. <~>A randomised, placebo-controlled 12-week study. Thromb Haemost . 2000; 83 29-34
- 24 Ridker P M, Hennekens C H, Rifai N, Buring J E, Manson J E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation . 1999; 100 713-716
- 25 Cushman M, Legault C, Barrett-Connor E. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation . 1999; 100 717-722
- 26 Ridker P M, Buring J E, Shih J, Matias M, Hennekens C H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation . 1998; 98 731-733
- 27 Ridker P M, Cushman M, Stampfer M J, Tracy R P, Hennekens C H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation . 1998; 97 425-428
- 28 Sattar N, Perera M, Small M, Lumsden M A. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet . 1999; 354 487-488
- 29 Cornu C, Mercier C, Ffrench P. Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. Maturitas . 2000; 37 95-104
- 30 Lunt H, Brown L J. Self-reported changes in capillary glucose and insulin requirements during the menstrual cycle. Diabet Med . 1996; 13 525-530
- 31 Hjortland M C, McNamara P M, Kannel W B. Some atherogenic concomitants of menopause: the Framingham Study. Am J Epidemiol . 1976; 103 304-311
- 32 Matthews K A, Meilahn E, Kuller L H, Kelsey S F, Caggiula A W, Wing R R. Menopause and risk factors for coronary heart disease. N Engl J Med . 1989; 321 641-646
- 33 Lindheim S R, Presser S C, Ditkoff E C, Vijod M A, Stanczyk F Z, Lobo R A. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril . 1993; 60 664-667
- 34 Walton C, Godsland I F, Proudler A J, Wynn V, Stevenson J C. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest . 1993; 23 466-473
- 35 Toth M J, Sites C K, Eltabbakh G H, Poehlman E T. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care . 2000; 23 801-806
- 36 Andersson B, Mattsson L A, Hahn L. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab . 1997; 82 638-643
- 37 Brussaard H E, Gevers Leuven A J, Frolich M, Kluft C, Krans H M. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia . 1997; 40 843-849
- 38 Owens D, Collins P B, Johnson A, Tomkin G H. Lipoproteins and low-dose estradiol replacement therapy in post-menopausal type 2 diabetic patients: the effect of addition of norethisterone acetate. Diabet Med . 2000; 17 308-315
- 39 Goldman J A, Ovadia J L. The effect of estrogen on intravenous glucose tolerance in women. Am J Obstet Gynecol . 1969; 103 172-178
- 40 Thom M, Chakravarti S, Oram D H, Studd J W. Effect of hormone replacement therapy on glucose tolerance in postmenopausal women. Br J Obstet Gynaecol . 1977; 84 776-783
- 41 Lilley S H, Spivey J M, Vadlamudi S, Otvos J, Cummings D M, Barakat H. Lipid and lipoprotein responses to oral combined hormone replacement therapy in normolipemic obese women with controlled type 2 diabetes mellitus. J Clin Pharmacol . 1998; 38 1107-1115
- 42 Samaras K, Hayward C S, Sullivan D, Kelly R P, Campbell L V. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. Diabetes Care . 1999; 22 1401-1407
- 43 Felmeden D C, Lip G Y. Hormone replacement therapy and hypertension. Blood Press . 2000; 9 246-249
- 44 Kannel W B. Oral contraceptive hypertension and thromboembolism. Int J Gynaecol Obstet . 1978; 16 466-472
- 45 August P, Oparil S. Hypertension in women. J Clin Endocrinol Metab . 1999; 84 1862-1866
- 46 Amigoni S, Morelli P, Parazzini F, Chatenoud L. Determinants of elevated blood pressure in women around menopause: results from a cross-sectional study in Italy. Maturitas . 2000; 34 25-32
- 47 Gilligan D M, Badar D M, Panza J A, Quyyumi A A, Cannon III O R. Acute vascular effects of estrogen in postmenopausal women. Circulation . 1994; 90 786-791
- 48 Hayward C S, Samaras K, Campbell L, Kelly R P. Effect of combination hormone replacement therapy on ambulatory blood pressure and arterial stiffness in diabetic postmenopausal women. Am J Hypertens . 2001; 14 699-703
- 49 Knopp R H, Warth M R, Carrol C J. Lipid metabolism in pregnancy. I. Changes in lipoprotein triglyceride and cholesterol in normal pregnancy and the effects of diabetes mellitus. J Reprod Med . 1973; 10 95-101
- 50 Knopp R H, Broyles F E, Cheung M, Moore K, Marcovina S, Chandler W L. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception . 2001; 63 1-11
- 51 Falco C, Tormo G, Estelles A. Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy. Haematologica . 2001; 86 92-98
- 52 Morrisett J D. The role of lipoprotein(a) in atherosclerosis. Curr Atheroscler Rep . 2000; 2 243-250
- 53 Robinson J C, Folsom A R, Nabulsi A A, Watson R, Brancati F L, Cai J. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes?. <~>The Atherosclerosis Risk in Communities Study Investigators. Diabetes Care . 1996; 19 480-485
- 54 Hoogerbrugge N. Hypertriglyceridemie door oestrogeengebruik. Ned Tijdschr Geneeskd . 1997; 141 1225-1227
- 55 Manning P J, Allum A, Jones S, Sutherland W H, Williams S M. The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial. Arch Intern Med . 2001; 161 1772-1776
- 56 Perera M, Sattar N, Petrie J R. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab . 2001; 86 1140-1143
- 57 Friday K E, Dong C, Fontenot R U. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab . 2001; 86 48-52
- 58 Manwaring P, Morfis L, Diamond T, Howes L G. The effects of hormone replacement therapy on plasma lipids in type II diabetes. Maturitas . 2000; 34 239-247
- 59 Dunaif A, Utian W H, Brandenburg S L. Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: consensus opinion of The North American Menopause Society. Menopause . 2000; 7 87-95
- 60 Andersson B. Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment. Drugs Aging . 2000; 17 399-410